{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:34:25Z","timestamp":1790116465684,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40119-024-00352-x","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T06:02:16Z","timestamp":1706853736000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Factor\u00a0XI Inhibitors: A New Horizon in Anticoagulation Therapy"],"prefix":"10.1007","volume":"13","author":[{"given":"Jo\u00e3o","family":"Presume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Ribeiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"issue":"7","key":"352_CR1","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1160\/TH16-10-0807","volume":"117","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost. 2017;117(7):1283\u20138.","journal-title":"Thromb Haemost"},{"issue":"6","key":"352_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","volume":"78","author":"C Hsu","year":"2021","unstructured":"Hsu C, Hutt E, Gailani D, Weitz JI. Factor\u00a0XI inhibition to uncouple. JACC. 2021;78(6):625\u201331.","journal-title":"JACC"},{"issue":"13","key":"352_CR3","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206\u201314.","journal-title":"N Engl J Med"},{"issue":"7","key":"352_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2300067","DOI":"10.1056\/EVIDoa2300067","volume":"2","author":"TY Wang","year":"2023","unstructured":"Wang TY, Svensson LG, Wen J, et al. Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM Evid. 2023;2(7):EVIDoa2300067.","journal-title":"NEJM Evid"},{"issue":"1","key":"352_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","volume":"81","author":"CD Khairani","year":"2023","unstructured":"Khairani CD, Bejjani A, Piazza G, et al. Direct oral anticoagulants vs vitamin\u00a0K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol. 2023;81(1):16\u201330.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"352_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","volume":"387","author":"SJ Connolly","year":"2022","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387(11):978\u201388.","journal-title":"N Engl J Med"},{"issue":"10","key":"352_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"7","key":"352_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2217\/cer-2019-0197","volume":"9","author":"CS Fern\u00e1ndez","year":"2020","unstructured":"Fern\u00e1ndez CS, Gull\u00f3n A, Formiga F. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation. J Comp Eff Res. 2020;9(7):509\u201323.","journal-title":"J Comp Eff Res"},{"issue":"6","key":"352_CR9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.amjmed.2020.12.022","volume":"134","author":"H Ashraf","year":"2021","unstructured":"Ashraf H, Agasthi P, Shanbhag A, et al. Long-term clinical outcomes of underdosed direct oral anticoagulants in patients with atrial fibrillation and atrial flutter. Am J Med. 2021;134(6):788\u201396.","journal-title":"Am J Med"},{"issue":"4","key":"352_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","volume":"147","author":"H Reinecke","year":"2023","unstructured":"Reinecke H, Engelbertz C, Bauersachs R, et al. A randomized controlled trial comparing apixaban with the vitamin\u00a0K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation. 2023;147(4):296\u2013309.","journal-title":"Circulation"},{"issue":"23","key":"352_CR11","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022;146(23):1735\u201345.","journal-title":"Circulation"},{"key":"352_CR12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1126\/science.1652157","volume":"253","author":"D Gailani","year":"1991","unstructured":"Gailani D, Broze G. Factor\u00a0XI activation in a revised model of blood coagulation. Science. 1991;253:909\u201312.","journal-title":"Science"},{"key":"352_CR13","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/S0049-3848(16)30363-2","volume":"141","author":"JI Weitz","year":"2016","unstructured":"Weitz JI. Factor\u00a0XI and factor\u00a0XII as targets for new anticoagulants. Thromb Res. 2016;141:S40\u20135.","journal-title":"Thromb Res"},{"issue":"11","key":"352_CR14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","volume":"147","author":"A Greco","year":"2023","unstructured":"Greco A, Laudani C, Spagnolo M, et al. Pharmacology and clinical development of factor\u00a0XI inhibitors. Circulation. 2023;147(11):897\u2013913.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"352_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1538-7836.2009.03395.x","volume":"7","author":"U Seligsohn","year":"2009","unstructured":"Seligsohn U. Factor\u00a0XI deficiency in humans. J Thromb Haemost. 2009;7(Suppl 1):84\u20137.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"352_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M, Hirsch J, Kotler A, et al. Factor\u00a0XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129(9):1210\u20135.","journal-title":"Blood"},{"issue":"7","key":"352_CR17","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","volume":"36","author":"D Gailani","year":"2016","unstructured":"Gailani D, Gruber A. Factor\u00a0XI as a therapeutic target. Arterioscler Thromb Vasc Biol. 2016;36(7):1316\u201322.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"352_CR18","first-page":"00851","volume":"1538\u20137836","author":"S Yuan","year":"2023","unstructured":"Yuan S, Xu F, Zhang H, et al. Proteomic insights into modifiable risk of venous thromboembolism and cardiovascular comorbidities. J Thromb Haemost. 2023;1538\u20137836(23):00851\u20136.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"352_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","volume":"44","author":"R De Caterina","year":"2023","unstructured":"De Caterina R, Prisco D, Eikelboom JW. Factor\u00a0XI inhibitors: cardiovascular perspectives. Eur Heart J. 2023;44(4):280\u201392.","journal-title":"Eur Heart J"},{"key":"352_CR20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/ATVBAHA.117.309664","volume":"38","author":"JI Weitz","year":"2018","unstructured":"Weitz JI, Fredenburgh JC. 2017 Scientific sessions Sol Sherry distinguished lecture factor\u00a0XI as a target for new anticoagulants. Arter Thromb Vasc Biol. 2018;38:304\u201310.","journal-title":"Arter Thromb Vasc Biol"},{"key":"352_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/a-1384-3715","volume":"41","author":"JC Fredenburgh","year":"2021","unstructured":"Fredenburgh JC, Weitz JI. Factor\u00a0XI as a target for new anticoagulants. Hamostaseologie. 2021;41:104\u201310.","journal-title":"Hamostaseologie"},{"issue":"18","key":"352_CR22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa011099","volume":"345","author":"KA Bauer","year":"2001","unstructured":"Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345(18):1298\u2013304.","journal-title":"N Engl J Med"},{"issue":"9717","key":"352_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","volume":"375","author":"MR Lassen","year":"2010","unstructured":"Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807\u201315.","journal-title":"Lancet"},{"key":"352_CR24","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385:2161\u201372.","journal-title":"N Engl J Med"},{"issue":"2","key":"352_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty the FOXTROT randomized clinical trial. JAMA. 2020;323(2):130\u20139.","journal-title":"JAMA"},{"key":"352_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, Bethune C, Bhanot S, et al. Factor\u00a0XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232\u201340.","journal-title":"N Engl J Med"},{"key":"352_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385:609\u201317.","journal-title":"N Engl J Med"},{"issue":"12","key":"352_CR28","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1111\/jth.15890","volume":"20","author":"J Presume","year":"2022","unstructured":"Presume J, Ferreira J, Ribeiras R, Mendes M. Achieving higher efficacy without compromising safety with factor\u00a0XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery\u2014systematic review and meta-analysis. J Thromb Haemost. 2022;20(12):2930\u20138.","journal-title":"J Thromb Haemost"},{"issue":"9658","key":"352_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","volume":"373","author":"T Watson","year":"2009","unstructured":"Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow\u2019s triad revisited. Lancet. 2009;373(9658):155\u201366.","journal-title":"Lancet"},{"key":"352_CR30","doi-asserted-by":"crossref","unstructured":"O\u2019Brien EC, Holmes DJN, Thomas L, et al. Therapeutic strategies following major, clinically relevant nonmajor, and nuisance bleeding in atrial fibrillation: findings from ORBIT-AF. J Am Heart Assoc. 2018;7(12):e006391.","DOI":"10.1161\/JAHA.117.006391"},{"issue":"11","key":"352_CR31","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","volume":"50","author":"B Georgi","year":"2019","unstructured":"Georgi B, Mielke J, Chaffin M, et al. Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor\u00a0XI. Stroke. 2019;50(11):3004\u201312.","journal-title":"Stroke"},{"key":"352_CR32","unstructured":"Hughes S. Asundexian phase\u00a03 AF study halted for lack of efficacy. Medscape. 2023. https:\/\/www.medscape.com\/viewarticle\/998665?form=fpf. Accessed 5 Jan  2024."},{"issue":"22","key":"352_CR33","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"1","key":"352_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319.","journal-title":"N Engl J Med"},{"issue":"14","key":"352_CR35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"352_CR36","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1182\/blood-2003-01-0324","volume":"102","author":"A Gruber","year":"2003","unstructured":"Gruber A, Hanson SR. Factor\u00a0XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood. 2003;102(3):953\u20135.","journal-title":"Blood"},{"issue":"7","key":"352_CR37","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1021\/acsptsci.3c00052","volume":"6","author":"S Wichaiyo","year":"2023","unstructured":"Wichaiyo S, Parichatikanond W, Visansirikul S, Saengklub N, Rattanavipanon W. Determination of the potential clinical benefits of small molecule factor\u00a0XIa inhibitors in arterial thrombosis. ACS Pharmacol Transl Sci. 2023;6(7):970\u201381.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"5","key":"352_CR38","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1055\/s-0041-1735971","volume":"122","author":"S Sharman Moser","year":"2022","unstructured":"Sharman Moser S, Chodick G, Ni YG, et al. The association between factor\u00a0XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events. Thromb Haemost. 2022;122(5):808\u201317.","journal-title":"Thromb Haemost"},{"issue":"16","key":"352_CR39","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","volume":"146","author":"SV Rao","year":"2022","unstructured":"Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase\u00a02, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor\u00a0XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022;146(16):1196\u2013206.","journal-title":"Circulation"},{"issue":"8","key":"352_CR40","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","volume":"111","author":"O Salomon","year":"2008","unstructured":"Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor\u00a0XI deficiency. Blood. 2008;111(8):4113\u20137.","journal-title":"Blood"},{"issue":"10357","key":"352_CR41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, et al. Factor\u00a0XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase\u00a02b trial. Lancet. 2022;400(10357):997\u20131007.","journal-title":"Lancet"},{"issue":"S1","key":"352_CR42","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1111\/jth.12961","volume":"13","author":"IH Jaffer","year":"2015","unstructured":"Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it? J Thromb Haemost. 2015;13(S1):S72-81.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"352_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1055\/s-0037-1603937","volume":"44","author":"B Tillman","year":"2019","unstructured":"Tillman B, Gailani D. Inhibition of factor\u00a0XI and factor\u00a0XII for prevention of thrombosis induced by artificial surfaces. Semin Thromb Hemost. 2019;44(1):60\u20139.","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"352_CR44","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","volume":"123","author":"JW Yau","year":"2014","unstructured":"Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor\u00a0XI or factor\u00a0XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123(13):2102\u20137.","journal-title":"Blood"},{"key":"352_CR45","doi-asserted-by":"crossref","unstructured":"David T, Kim YC, Ely LK, et al. Factor\u00a0XIa-specific IgG and a reversal agent to probe factor\u00a0XI function in thrombosis and hemostasis. Sci Transl Med. 2016;8(353):353ra112.","DOI":"10.1126\/scitranslmed.aaf4331"},{"issue":"6","key":"352_CR46","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","volume":"100","author":"J Eikelboom","year":"2021","unstructured":"Eikelboom J, Floege J, Thadhani R, Weitz JI, Winkelmayer WC. Anticoagulation in patients with kidney failure on dialysis: factor\u00a0XI as a therapeutic target. Kidney Int. 2021;100(6):1199\u2013207.","journal-title":"Kidney Int"},{"issue":"6","key":"352_CR47","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","volume":"32","author":"AS de Vriese","year":"2021","unstructured":"de Vriese AS, Caluw\u00e9 R, van der Meersch H, de Boeck K, de Bacquer D. Safety and efficacy of vitamin\u00a0K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol. 2021;32(6):1474\u201383.","journal-title":"J Am Soc Nephrol"},{"key":"352_CR48","doi-asserted-by":"crossref","unstructured":"Poenou G, Heestermans M, Lafaie L, et al. Inhibition of factor\u00a0XI: a new era in the treatment of venous thromboembolism in cancer patients? Int J Mol Sci. 2023;24(19):14433.","DOI":"10.3390\/ijms241914433"},{"issue":"22","key":"352_CR49","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","volume":"329","author":"D Schrag","year":"2023","unstructured":"Schrag D, Uno H, Rosovsky R, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329(22):1924\u201333.","journal-title":"JAMA"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00352-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-024-00352-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00352-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T12:04:14Z","timestamp":1709121854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-024-00352-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1007\/s40119-024-00352-x","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jo\u00e3o Presume declares that he has no competing interests. Jorge Ferreira has received consulting and speaker fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis and Pfizer. Regina Ribeiras declares that he has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}